Navigation Links
Inovio Pharmaceuticals' Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
Date:8/15/2013

and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis C virus. Partners and collaborators include the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove sa
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Reports 2013 Second Quarter Financial Results
2. Inovio Pharmaceuticals Responds to Market Activity
3. Inovio Pharmaceuticals Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
4. Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovios Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
5. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
6. Inovio Pharmaceuticals to Present at OneMedForumNY 2013 Investor Conference
7. Inovios Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
8. Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
9. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
10. Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
11. Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... -- Medela announced today that it has reached a five-year ... the exclusive distributor of the ABC Enteral Feeding Pump ... Pump. Through this agreement, Medela will be in a ... by offering a comprehensive set of products and programs. ... to the delivery of human milk to at-risk infants. ...
(Date:9/23/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... focus on China , announces the ... and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. to ... connection with the recently announced acquisition of greater ...
(Date:9/23/2014)... CARLOS, Calif. , Sept. 23, 2014 /PRNewswire/ ... company, today confirmed the initiation of human safety ... forms of addiction. A single dose of 18-MC, ... safety study conducted by Savant,s South American partner, ... experimental drug. Savant HWP plans to develop 18-MC ...
Breaking Medicine Technology:Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 2Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 3
... , SAN DIEGO, Nov. 6 Ardea Biosciences, Inc. ... the development of small-molecule therapeutics for the treatment of ... recent accomplishments and financial results for the third quarter ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091104/ARDEALOGO ) , "Since our last ...
... Inc., in collaboration with scientists at the Centers for Disease ... of Hong Kong, announced today the publication of two articles ... studies suggest that DAS181 (Fludase ® ) may play a ... Pandemic Influenza A(H1N1) and drug-resistant influenza. , DAS181 is ...
Cached Medicine Technology:Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 8NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4
(Date:9/23/2014)... Randy Dotinga HealthDay Reporter ... cholesterol-lowering drugs while in the hospital for a hemorrhagic stroke ... than four times more likely to survive than people who ... People taking the commonly used drugs known as statins were ... to a rehabilitation facility, the study reports. When it ...
(Date:9/23/2014)... have published the first study to extensively characterize ... The Journal of Allergy and Clinical Immunology , ... has high levels of eosinophils in the blood ... mechanisms and has a gene expression pattern (transcriptome) ... disorder, eosinophilic esophagitis (EoE). , Eosinophilic gastrointestinal ...
(Date:9/23/2014)... and a researcher in UTSA,s South Texas Center for ... Ruhr University in Bochum, Germany to understand how humans ... week in an article published by the Proceedings ... is an acute infection caused by ingestion of food ... Vibrio cholerae . An estimated three to five million ...
(Date:9/23/2014)... a potential source of student diversity for medical ... however, there are significant challenges to enhancing the ... medical schools. The authors recommend that medical school ... be more inclusive of community college students. , ... Francisco and San Jose City College found that, ...
(Date:9/23/2014)... Affordable Care Act "Obamacare" was signed into ... the U.S. healthcare system since the 1960s. Designed to ... widely decried as an unwarranted intrusion into the affairs ... comparative study of healthcare systems in six Western countries, ... , supports a move away from privatized medicine toward ...
Breaking Medicine News(10 mins):Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3Health News:Advancing the understanding of an understudied food allergy disorder 2Health News:Advancing the understanding of an understudied food allergy disorder 3Health News:UTSA microbiologists discover regulatory thermometer that controls cholera 2Health News:Medical students who attended community college likelier to serve poor communities 2Health News:Life, liberty, and the pursuit of healthcare? 2
... disorders may be round the corner as scientists have traced the ... To start with they have experimented on the rat brain and ... first time that such advances have been made vis-à-vis eating disorders. ... sets of brain cells respond to hormones, among them two proteins ...
... cancer center, New Orleans have identified and isolated a protein ... cancer to the liver. The protein, called Pa 28 alpha, ... lead investigator Justinian Ngaiza, a clinical fellow in hematology/oncology at ... To isolate the protein, Ngaiza and colleagues took ...
... that would alter the lives of millions, scientists at the ... simple method of administering protein based drugs such as insulin ... manufacture of tiny protein coated micro crystals can pass through ... powder inhalers similar to those used by asthma sufferers.// ...
... herpes virus that causes infectious mononucleosis, Epstein-Barr virus (EBV), has ... disease. But no one has carefully studied the possible link ... Dr. Christina A. Clarke from Northern California Cancer Center in ... This virus is believed to increase the risk for the ...
... are in the pipeline to reduce risk factors of heart ... heart attacks. Dr. Carl R. Alving of the Walter Reed ... implicating various infectious agents in the development of atherosclerosis, or ... may reduce heart disease risk factors such as high cholesterol. ...
... journal Human Reproduction on Friday last, announced that a group ... of babies. , But Jacques ... the United States, denied that the children had been born ... first human babies whose genetic make-up had been artificially altered ...
Cached Medicine News:
... 4, 8, or 12 channel pipettors. Angled ... nearly all of the solution. Corners have ... Made of natural virgin polystyrene containing no ... 152 mm L x 35 mm H ...
Volume: 5 ml; Volume Graduation: 1/10 ml...
... for use with measuring pipettes, enables you to ... works with all types of glass or plastic ... to 100 mL.Gilsons Pipette Aid is equipped with ... protect the mechanism of the device from contamination ...
Application: Safe and convenient filling and dispensing of glass and plastic pipets....
Medicine Products: